lncRNA PVT1 in the Pathogenesis and Clinical Management of Renal Cell Carcinoma

BOHOŠOVÁ, Júlia, Adéla KUBÍČKOVÁ and Ondřej SLABÝ. lncRNA PVT1 in the Pathogenesis and Clinical Management of Renal Cell Carcinoma. Biomolecules. BASEL: MDPI, 2021, vol. 11, No 5, p. 1-12. ISSN 2218-273X. Available from: https://dx.doi.org/10.3390/biom11050664.

Basic information

• Original name: lncRNA PVT1 in the Pathogenesis and Clinical Management of Renal Cell Carcinoma
• Authors: BOHOŠOVÁ, Júlia (703 Slovakia, belonging to the institution), Adéla KUBÍČKOVÁ (203 Czech Republic, belonging to the institution) and Ondřej SLABÝ (203 Czech Republic, guarantor, belonging to the institution).
• Edition: Biomolecules, BASEL, MDPI, 2021, 2218-273X.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 10608 Biochemistry and molecular biology
• Country of publisher: Switzerland
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 6.064
• RIV identification code: RIV/00216224:14110/21:00120232
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.3390/biom11050664
• UT WoS: 000653480900001
• Keywords in English: biomarker; prognosis; diagnosis; long non-coding RNA; tumorigenesis
• Tags: 14110513, 14110516, podil, rivok
• Tags: International impact, Reviewed

Abstract

LncRNA PVT1 (plasmacytoma variant translocation 1) has become a staple of the lncRNA profile in patients with renal cell carcinoma (RCC). Common dysregulation in renal tumors outlines the essential role of PVT1 in the development of RCC. There is already a plethora of publications trying to uncover the cellular mechanisms of PVT1-mediated regulation and its potential exploitation in management of RCC. In this review, we summarize the literature focused on PVT1 in RCC and aim to synthesize the current knowledge on its role in the cells of the kidney. Further, we provide an overview of the lncRNA profiling studies that have identified a more or less significant association of PVT1 with the clinical behavior of RCC. Based on our search, we analyzed the 17 scientific papers discussed in this review that provide robust support for the indispensable role of PVT1 in RCC development and future personalized therapy.

Links

• NV18-03-00554, research and development project: Name: Molekulární klasifikace renálního buněčného karcinomu založená na expresi dlouhých nekódujících RNA a její využití v diagnostice, předpovědi prognózy a terapii

Investor: Ministry of Health of the CR